Wednesday, February 10, 2010, 6:43am EST - Canadian Markets open in 2 hours and 47 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Pharmasset, Inc. (VRUS)

 On Feb 9: 22.68 USD   0.00 (0.00%)  
MORE ON VRUS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Pharmasset, Inc. (NGM:VRUS) Delayed quote dataEdit
Last Trade: 22.68 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 22.68
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: 29.00
Day's Range: N/A - N/A
52wk Range: 7.62 - 24.61
Volume: 0
Avg Vol (3m): 145,808
Market Cap: 641.32M
P/E (ttm): N/A
EPS (ttm): -0.46
Div & Yield: N/A (N/A%)
Pharmasset, Inc. (VRUS)
1d  5d  3m  6m  1y  2y  5y 
 Add VRUS to Portfolio   Download Data

HEADLINES
• PHARMASSET INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Tue 4:24pm)
• Pharmasset Reports Fiscal First Quarter 2010 Financial Results
PRNewswire (Tue 4:00pm)
• Pharmasset Announces Exercise of Underwriter's Option
PRNewswire (Fri, Jan 29)
• PHARMASSET INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
EDGAR Online (Thu, Jan 28)
• Pharmasset Prices Underwritten Offering of Common Stock
PRNewswire (Thu, Jan 28)
• Pharmasset Announces Proposed Public Offering of Common Stock
PRNewswire (Wed, Jan 27)
• PHARMASSET INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Mon, Jan 25)
• Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851
PRNewswire (Thu, Jan 21)
• Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
PRNewswire (Fri, Jan 8)
• Anadys hepatitis C drug meets key study goals
AP (Thu, Dec 17)
More Headlines for VRUS...
ANALYST
EPS Est (next year) (Sep-08) : -1.46
EPS Est (in 2 years) (Sep-09) : -1.61
Avg Rec (current)*: 1.5
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections. Its primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices